Skip to main content
. 2015 Oct 12;10(6):3722–3726. doi: 10.3892/ol.2015.3796

Table I.

Characteristic of the 31 patients with epithelial ovarian carcinoma.

Case no. Tumor FHOC Age, years CA-125, U/mla EOC Histologyb Grade FIGO stage Residual disease, cmc OS time, months
  1   2 Negative 63 >600 Serous G3 IIIC >5   12.3
  2   21 Negative 58 >600 Serous G1 IIIC >5   10.1
  3   23 Negative 42 1161 Undifferentiated G3 IIIC <1 106.7
  4   32 Negative 74 4207 Serous G3 IIIC 1–5   6.9
  5   37 Positive 55   399 Serous G3 IIIC 1–5   33.2
  6   40 Negative 48 No data Serous G1 IIIC <1   7.2
  7   49 Negative 41 No data Serous G2 IIIC <1   63.0
  8   56 Positive 46   654 Serous G3 IIIC <1 104.3
  9   58 Negative 77 No data Serous G2 IIIC <1   0.3
10   63 Negative 60     14 Serous G1 IC 0 32.5
11   74 Positive 45   599 Serous G2 IV >5   19.6
12   93 Negative 75   319 Serous G3 IIIC 1–5   19.9
13 102 Negative 32   326 Clear cell G2 IIC 0 130.9
14 118 Negative 79 7368 Serous G2 IIIC >5   35.0
15 127 Negative 47   198 Undifferentiated G3 IIIB <1 100.4
16 135 Negative 55 >600 Serous G1 IIIC 1–5   16.9
17 137 Negative 63 No data Serous G1 IIIC <1   17.8
18 150 Negative 56   403 Serous G3 IIIC <1   0.2
19 153 Positive 48 1089 Serous G3 IIIC <1   87.3
20 157 Negative 37 >600 Serous G2 IIIC <1   21.5
21 165 Negative 59     10 Serous G2 IIIC >5   14.6
22 170 Positive 78 No data Serous G1 IIIC >5   18.0
23 172 Negative 54 1001 Serous G2 IIIC 1–5   94.3
24 182 Negative 73   563 Undifferentiated G3 IV <1   26.6
25 200 Negative 73 4851 Serous G3 IV <1   7.0
26 211 Positive 82   802 Serous G2 IIIA <1   41.7
27 218 Negative 88 No data Serous G1 IV <1 No FU
28 219 Negative 54   311 Undifferentiated G3 IIIC 1–5   84.5
29 257 Negative 62   300 Serous G2 IIIC >5   25.8
30 766 Positive 46   156 Endometrioid G3 IIB 0   43.3
31 792 Negative 36   136 Serous G1 IIIB 0 106.9
a

CA125 normal range, 4–41 U/ml (29).

b

(15).

c

Residual disease, R, is presented as the diameter of the largest tumor left after primary surgery; FHOC, familiar history of ovarian cancer. OS, overall survival; NA, not applicable; CA-125, cancer antigen 125; FIGO, International Federation of Gynecology and Obstetrics; FU, follow-up.